Faculty Appointments
Research Associate Professor of Medicine
Education
Ph.D., East Carolina University, Greenville, North CarolinaB.S., University of Illinois, Chicago, Illinois
Publications
Lehmann BD, Colaprico A, Silva TC, Chen J, An H, Ban Y, Huang H, Wang L, James JL, Balko JM, Gonzalez-Ericsson PI, Sanders ME, Zhang B, Pietenpol JA, Chen XS. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nat Commun. 2021 Nov 11/1/2021; 12(1): 6276. PMID: 34725325, PMCID: PMC8560912, PII: 10.1038/s41467-021-26502-6, DOI: 10.1038/s41467-021-26502-6, ISSN: 2041-1723.
Redman-Rivera LN, Shaver TM, Jin H, Marshall CB, Schafer JM, Sheng Q, Hongo RA, Beckermann KE, Wheeler FC, Lehmann BD, Pietenpol JA. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes. Nat Commun. 2021 Aug 8/31/2021; 12(1): 5184. PMID: 34465782, PMCID: PMC8408227, PII: 10.1038/s41467-021-25359-z, DOI: 10.1038/s41467-021-25359-z, ISSN: 2041-1723.
Marshall CB, Beeler JS, Lehmann BD, Gonzalez-Ericsson P, Sanchez V, Sanders ME, Boyd KL, Pietenpol JA. Tissue-specific expression of p73 and p63 isoforms in human tissues. Cell Death Dis. 2021 Jul 7/27/2021; 12(8): 745. PMID: 34315849, PMCID: PMC8316356, PII: 10.1038/s41419-021-04017-8, DOI: 10.1038/s41419-021-04017-8, ISSN: 2041-4889.
Johnstone CN, Tu Y, Langenbach S, Baloyan D, Pattison AD, Lock P, Britt KL, Lehmann BD, Beilharz TH, Ernst M, Anderson RL, Stewart AG. Annexin A1 Is Required for Efficient Tumor Initiation and Cancer Stem Cell Maintenance in a Model of Human Breast Cancer. Cancers (Basel). 2021 Mar 3/8/2021; 13(5): PMID: 33800279, PMCID: PMC7962654, PII: cancers13051154, DOI: 10.3390/cancers13051154, ISSN: 2072-6694.
Lu M, Sha Y, Silva TC, Colaprico A, Sun X, Ban Y, Wang L, Lehmann BD, Chen XS. LR Hunting: A Random Forest Based Cell-Cell Interaction Discovery Method for Single-Cell Gene Expression Data. Front Genet. 2021; 12: 708835. PMID: 34497635, PMCID: PMC8420858, DOI: 10.3389/fgene.2021.708835, ISSN: 1664-8021.
Lehmann BD, Abramson VG, Sanders ME, Mayer EL, Haddad TC, Nanda R, Van Poznak C, Storniolo AM, Nangia JR, Gonzalez-Ericsson PI, Sanchez V, Johnson KN, Abramson RG, Chen SC, Shyr Y, Arteaga CL, Wolff AC, Pietenpol JA, . TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. Clin Cancer Res [print-electronic]. 2020 May 5/1/2020; 26(9): 2111-23. PMID: 31822498, PMCID: PMC7196503, PII: 1078-0432.CCR-19-2170, DOI: 10.1158/1078-0432.CCR-19-2170, ISSN: 1557-3265.
Schafer JM, Lehmann BD, Gonzalez-Ericsson PI, Marshall CB, Beeler JS, Redman LN, Jin H, Sanchez V, Stubbs MC, Scherle P, Johnson KN, Sheng Q, Roland JT, Bauer JA, Shyr Y, Chakravarthy B, Mobley BC, Hiebert SW, Balko JM, Sanders ME, Liu PCC, Pietenpol JA. Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. Sci Transl Med. 2020 Mar 3/11/2020; 12(534): PMID: 32161105, PMCID: PMC7427123, PII: 12/534/eaaw8275, DOI: 10.1126/scitranslmed.aaw8275, ISSN: 1946-6242.
Korolkova OY, Widatalla SE, Whalen DS, Nangami GN, Abimbola A, Williams SD, Beasley HK, Reisenbichler E, Washington MK, Ochieng J, Mayer IA, Lehmann BD, Sakwe AM. Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets. PLoS One. 2020; 15(4): e0231711. PMID: 32298357, PMCID: PMC7162501, PII: PONE-D-19-34943, DOI: 10.1371/journal.pone.0231711, ISSN: 1932-6203.
Lehmann BD, Shaver TM, Johnson DB, Li Z, Gonzalez-Ericsson PI, Sánchez V, Shyr Y, Sanders ME, Pietenpol JA. Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations. Mol Cancer Res [print-electronic]. 2019 Sep; 17(9): 1842-53. PMID: 31186280, PMCID: PMC6726520, PII: 1541-7786.MCR-19-0257, DOI: 10.1158/1541-7786.MCR-19-0257, ISSN: 1557-3125.
Whalen DS, Widatalla SE, Korolkova OY, Nangami GS, Beasley HK, Williams SD, Virgous C, Lehmann BD, Ochieng J, Sakwe AM. Implication of calcium activated RasGRF2 in Annexin A6-mediated breast tumor cell growth and motility. Oncotarget. 2019 Jan 1/4/2019; 10(2): 133-51. PMID: 30719209, PMCID: PMC6349432, PII: 26512, DOI: 10.18632/oncotarget.26512, ISSN: 1949-2553.
Guo Y, Yu H, Wang J, Sheng Q, Zhao S, Zhao YY, Lehmann BD. The Landscape of Small Non-Coding RNAs in Triple-Negative Breast Cancer. Genes (Basel). 2018 Jan 1/10/2018; 9(1): PMID: 29320459, PMCID: PMC5793181, PII: genes9010029, DOI: 10.3390/genes9010029, ISSN: 2073-4425.
Zhang P, Lehmann BD, Samuels DC, Zhao S, Zhao YY, Shyr Y, Guo Y. Estimating relative mitochondrial DNA copy number using high throughput sequencing data. Genomics [print-electronic]. 2017 Oct; 109(5-6): 457-62. PMID: 28734953, PII: S0888-7543(17)30060-5, DOI: 10.1016/j.ygeno.2017.07.002, ISSN: 1089-8646.
Jovanovic B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Clin Cancer Res [print-electronic]. 2017 Aug 8/1/2017; 23(15): 4035-45. PMID: 28270498, PMCID: PMC5540799, PII: 1078-0432.CCR-16-3055, DOI: 10.1158/1078-0432.CCR-16-3055, ISSN: 1557-3265.
Jovanovic B, Sheng Q, Seitz RS, Lawrence KD, Morris SW, Thomas LR, Hout DR, Schweitzer BL, Guo Y, Pietenpol JA, Lehmann BD. Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. BMC Cancer. 2017 Apr 4/4/2017; 17(1): 241. PMID: 28376728, PMCID: PMC5379658, PII: 10.1186/s12885-017-3237-1, DOI: 10.1186/s12885-017-3237-1, ISSN: 1471-2407.
Zhang P, Lehmann BD, Shyr Y, Guo Y. The Utilization of Formalin Fixed-Paraffin-Embedded Specimens in High Throughput Genomic Studies. Int J Genomics [print-electronic]. 2017; 2017: 1926304. PMID: 28246590, PMCID: PMC5299160, DOI: 10.1155/2017/1926304, ISSN: 2314-436X.
Shaver TM, Lehmann BD, Beeler JS, Li CI, Li Z, Jin H, Stricker TP, Shyr Y, Pietenpol JA. Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies. Cancer Res [print-electronic]. 2016 Aug 8/15/2016; 76(16): 4850-60. PMID: 27231203, PMCID: PMC4987189, PII: 0008-5472.CAN-16-0058, DOI: 10.1158/0008-5472.CAN-16-0058, ISSN: 1538-7445.
Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, Lehmann BD, Pietenpol JA, Seitz RS. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. BMC Cancer. 2016 Feb 2/23/2016; 16: 143. PMID: 26908167, PMCID: PMC4763445, PII: 10.1186/s12885-016-2198-0, DOI: 10.1186/s12885-016-2198-0, ISSN: 1471-2407.
Lehmann BD, Jovanovic B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016; 11(6): e0157368. PMID: 27310713, PMCID: PMC4911051, PII: PONE-D-16-14357, DOI: 10.1371/journal.pone.0157368, ISSN: 1932-6203.
Lehmann BD, Pietenpol JA. Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast [print-electronic]. 2015 Nov; 24 Suppl 2(0 2): S36-40-S40. PMID: 26253813, PMCID: PMC4641762, PII: S0960-9776(15)00147-2, DOI: 10.1016/j.breast.2015.07.009, ISSN: 1532-3080.
Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ, Khabele D. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Oncotarget. 2015 Aug 8/28/2015; 6(25): 21353-68. PMID: 25972361, PMCID: PMC4673270, PII: 3860, DOI: 10.18632/oncotarget.3860, ISSN: 1949-2553.
Lehmann BD, Ding Y, Viox DJ, Jiang M, Zheng Y, Liao W, Chen X, Xiang W, Yi Y. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value. BMC Cancer. 2015 Mar 3/26/2015; 15: 179. PMID: 25886164, PMCID: PMC4404582, PII: 10.1186/s12885-015-1102-7, DOI: 10.1186/s12885-015-1102-7, ISSN: 1471-2407.
Lehmann BD, Pietenpol JA, Tan AR. Triple-negative breast cancer: molecular subtypes and new targets for therapy. Am Soc Clin Oncol Educ Book. 2015; e31-9-e39. PMID: 25993190, PII: 00115000e31, DOI: 10.14694/EdBook_AM.2015.35.e31, ISSN: 1548-8756.
Mohni KN, Thompson PS, Luzwick JW, Glick GG, Pendleton CS, Lehmann BD, Pietenpol JA, Cortez D. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. PLoS One. 2015; 10(5): e0125482. PMID: 25965342, PMCID: PMC4428765, PII: PONE-D-14-51553, DOI: 10.1371/journal.pone.0125482, ISSN: 1932-6203.
Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: implications for therapy. Cancer [print-electronic]. 2015 Jan 1/1/2015; 121(1): 8-16. PMID: 25043972, PMCID: PMC4270831, DOI: 10.1002/cncr.28914, ISSN: 1097-0142.
Guo Y, Zhao S, Lehmann BD, Sheng Q, Shaver TM, Stricker TP, Pietenpol JA, Shyr Y. Detection of internal exon deletion with exon Del. BMC Bioinformatics. 2014 Oct 10/16/2014; 15(1): 332. PMID: 25322818, PMCID: PMC4288651, PII: 1471-2105-15-332, DOI: 10.1186/1471-2105-15-332, ISSN: 1471-2105.
Feigin ME, Akshinthala SD, Araki K, Rosenberg AZ, Muthuswamy LB, Martin B, Lehmann BD, Berman HK, Pietenpol JA, Cardiff RD, Muthuswamy SK. Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer. Cancer Res [print-electronic]. 2014 Jun 6/1/2014; 74(11): 3180-94. PMID: 24662921, PMCID: PMC4096808, PII: 0008-5472.CAN-13-3415, DOI: 10.1158/0008-5472.CAN-13-3415, ISSN: 1538-7445.
Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clin Cancer Res. 2014 Feb 2/15/2014; 20(4): 782-90. PMID: 24536073, PMCID: PMC3962777, PII: 1078-0432.CCR-13-0583, DOI: 10.1158/1078-0432.CCR-13-0583, ISSN: 1557-3265.
Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov [print-electronic]. 2014 Feb; 4(2): 232-45. PMID: 24356096, PMCID: PMC3946308, PII: 2159-8290.CD-13-0286, DOI: 10.1158/2159-8290.CD-13-0286, ISSN: 2159-8290.
Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014 Jan; 232(2): 142-50. PMID: 24114677, PMCID: PMC4090031, DOI: 10.1002/path.4280, ISSN: 1096-9896.
Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res. 2013 Dec 12/15/2013; 19(24): 6696-702. PMID: 24345920, PMCID: PMC3880773, PII: 19/24/6696, DOI: 10.1158/1078-0432.CCR-13-1746, ISSN: 1557-3265.
Xiang Y, Qiu Q, Jiang M, Jin R, Lehmann BD, Strand DW, Jovanovic B, DeGraff DJ, Zheng Y, Yousif DA, Simmons CQ, Case TC, Yi J, Cates JM, Virostko J, He X, Jin X, Hayward SW, Matusik RJ, George AL, Yi Y. SPARCL1 suppresses metastasis in prostate cancer. Mol Oncol [print-electronic]. 2013 Dec; 7(6): 1019-30. PMID: 23916135, PMCID: PMC3838491, PII: S1574-7891(13)00105-1, DOI: 10.1016/j.molonc.2013.07.008, ISSN: 1878-0261.
Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res [print-electronic]. 2013 Oct 10/1/2013; 19(19): 5533-40. PMID: 23948975, PMCID: PMC3813597, PII: 1078-0432.CCR-13-0799, DOI: 10.1158/1078-0432.CCR-13-0799, ISSN: 1557-3265.
Qiu Q, Lu P, Xiang Y, Shyr Y, Chen X, Lehmann BD, Viox DJ, George AL, Yi Y. A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer. PLoS One [print-electronic]. 2013; 8(1): e54979. PMID: 23383020, PMCID: PMC3558433, PII: PONE-D-12-15536, DOI: 10.1371/journal.pone.0054979, ISSN: 1932-6203.
Lehmann BD, Pietenpol JA. Targeting mutant p53 in human tumors. J Clin Oncol [print-electronic]. 2012 Oct 10/10/2012; 30(29): 3648-50. PMID: 22965952, PII: JCO.2012.44.0412, DOI: 10.1200/JCO.2012.44.0412, ISSN: 1527-7755.
Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, Pietenpol JA. TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Cancer Inform [print-electronic]. 2012; 11: 147-56. PMID: 22872785, PMCID: PMC3412597, PII: cin-11-2012-147, DOI: 10.4137/CIN.S9983, ISSN: 1176-9351.
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011 Jul; 121(7): 2750-67. PMID: 21633166, PMCID: PMC3127435, PII: 45014, DOI: 10.1172/JCI45014, ISSN: 1558-8238.
Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Res [print-electronic]. 2010; 12(3): R41. PMID: 20576088, PMCID: PMC2917036, PII: bcr2595, DOI: 10.1186/bcr2595, ISSN: 1465-542X.
Redman-Rivera LN, Shaver TM, Jin H, Marshall CB, Schafer JM, Sheng Q, Hongo RA, Beckermann KE, Wheeler FC, Lehmann BD, Pietenpol JA. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes. Nat Commun. 2021 Aug 8/31/2021; 12(1): 5184. PMID: 34465782, PMCID: PMC8408227, PII: 10.1038/s41467-021-25359-z, DOI: 10.1038/s41467-021-25359-z, ISSN: 2041-1723.
Marshall CB, Beeler JS, Lehmann BD, Gonzalez-Ericsson P, Sanchez V, Sanders ME, Boyd KL, Pietenpol JA. Tissue-specific expression of p73 and p63 isoforms in human tissues. Cell Death Dis. 2021 Jul 7/27/2021; 12(8): 745. PMID: 34315849, PMCID: PMC8316356, PII: 10.1038/s41419-021-04017-8, DOI: 10.1038/s41419-021-04017-8, ISSN: 2041-4889.
Johnstone CN, Tu Y, Langenbach S, Baloyan D, Pattison AD, Lock P, Britt KL, Lehmann BD, Beilharz TH, Ernst M, Anderson RL, Stewart AG. Annexin A1 Is Required for Efficient Tumor Initiation and Cancer Stem Cell Maintenance in a Model of Human Breast Cancer. Cancers (Basel). 2021 Mar 3/8/2021; 13(5): PMID: 33800279, PMCID: PMC7962654, PII: cancers13051154, DOI: 10.3390/cancers13051154, ISSN: 2072-6694.
Lu M, Sha Y, Silva TC, Colaprico A, Sun X, Ban Y, Wang L, Lehmann BD, Chen XS. LR Hunting: A Random Forest Based Cell-Cell Interaction Discovery Method for Single-Cell Gene Expression Data. Front Genet. 2021; 12: 708835. PMID: 34497635, PMCID: PMC8420858, DOI: 10.3389/fgene.2021.708835, ISSN: 1664-8021.
Lehmann BD, Abramson VG, Sanders ME, Mayer EL, Haddad TC, Nanda R, Van Poznak C, Storniolo AM, Nangia JR, Gonzalez-Ericsson PI, Sanchez V, Johnson KN, Abramson RG, Chen SC, Shyr Y, Arteaga CL, Wolff AC, Pietenpol JA, . TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. Clin Cancer Res [print-electronic]. 2020 May 5/1/2020; 26(9): 2111-23. PMID: 31822498, PMCID: PMC7196503, PII: 1078-0432.CCR-19-2170, DOI: 10.1158/1078-0432.CCR-19-2170, ISSN: 1557-3265.
Schafer JM, Lehmann BD, Gonzalez-Ericsson PI, Marshall CB, Beeler JS, Redman LN, Jin H, Sanchez V, Stubbs MC, Scherle P, Johnson KN, Sheng Q, Roland JT, Bauer JA, Shyr Y, Chakravarthy B, Mobley BC, Hiebert SW, Balko JM, Sanders ME, Liu PCC, Pietenpol JA. Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. Sci Transl Med. 2020 Mar 3/11/2020; 12(534): PMID: 32161105, PMCID: PMC7427123, PII: 12/534/eaaw8275, DOI: 10.1126/scitranslmed.aaw8275, ISSN: 1946-6242.
Korolkova OY, Widatalla SE, Whalen DS, Nangami GN, Abimbola A, Williams SD, Beasley HK, Reisenbichler E, Washington MK, Ochieng J, Mayer IA, Lehmann BD, Sakwe AM. Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets. PLoS One. 2020; 15(4): e0231711. PMID: 32298357, PMCID: PMC7162501, PII: PONE-D-19-34943, DOI: 10.1371/journal.pone.0231711, ISSN: 1932-6203.
Lehmann BD, Shaver TM, Johnson DB, Li Z, Gonzalez-Ericsson PI, Sánchez V, Shyr Y, Sanders ME, Pietenpol JA. Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations. Mol Cancer Res [print-electronic]. 2019 Sep; 17(9): 1842-53. PMID: 31186280, PMCID: PMC6726520, PII: 1541-7786.MCR-19-0257, DOI: 10.1158/1541-7786.MCR-19-0257, ISSN: 1557-3125.
Whalen DS, Widatalla SE, Korolkova OY, Nangami GS, Beasley HK, Williams SD, Virgous C, Lehmann BD, Ochieng J, Sakwe AM. Implication of calcium activated RasGRF2 in Annexin A6-mediated breast tumor cell growth and motility. Oncotarget. 2019 Jan 1/4/2019; 10(2): 133-51. PMID: 30719209, PMCID: PMC6349432, PII: 26512, DOI: 10.18632/oncotarget.26512, ISSN: 1949-2553.
Guo Y, Yu H, Wang J, Sheng Q, Zhao S, Zhao YY, Lehmann BD. The Landscape of Small Non-Coding RNAs in Triple-Negative Breast Cancer. Genes (Basel). 2018 Jan 1/10/2018; 9(1): PMID: 29320459, PMCID: PMC5793181, PII: genes9010029, DOI: 10.3390/genes9010029, ISSN: 2073-4425.
Zhang P, Lehmann BD, Samuels DC, Zhao S, Zhao YY, Shyr Y, Guo Y. Estimating relative mitochondrial DNA copy number using high throughput sequencing data. Genomics [print-electronic]. 2017 Oct; 109(5-6): 457-62. PMID: 28734953, PII: S0888-7543(17)30060-5, DOI: 10.1016/j.ygeno.2017.07.002, ISSN: 1089-8646.
Jovanovic B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Clin Cancer Res [print-electronic]. 2017 Aug 8/1/2017; 23(15): 4035-45. PMID: 28270498, PMCID: PMC5540799, PII: 1078-0432.CCR-16-3055, DOI: 10.1158/1078-0432.CCR-16-3055, ISSN: 1557-3265.
Jovanovic B, Sheng Q, Seitz RS, Lawrence KD, Morris SW, Thomas LR, Hout DR, Schweitzer BL, Guo Y, Pietenpol JA, Lehmann BD. Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. BMC Cancer. 2017 Apr 4/4/2017; 17(1): 241. PMID: 28376728, PMCID: PMC5379658, PII: 10.1186/s12885-017-3237-1, DOI: 10.1186/s12885-017-3237-1, ISSN: 1471-2407.
Zhang P, Lehmann BD, Shyr Y, Guo Y. The Utilization of Formalin Fixed-Paraffin-Embedded Specimens in High Throughput Genomic Studies. Int J Genomics [print-electronic]. 2017; 2017: 1926304. PMID: 28246590, PMCID: PMC5299160, DOI: 10.1155/2017/1926304, ISSN: 2314-436X.
Shaver TM, Lehmann BD, Beeler JS, Li CI, Li Z, Jin H, Stricker TP, Shyr Y, Pietenpol JA. Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies. Cancer Res [print-electronic]. 2016 Aug 8/15/2016; 76(16): 4850-60. PMID: 27231203, PMCID: PMC4987189, PII: 0008-5472.CAN-16-0058, DOI: 10.1158/0008-5472.CAN-16-0058, ISSN: 1538-7445.
Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, Lehmann BD, Pietenpol JA, Seitz RS. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. BMC Cancer. 2016 Feb 2/23/2016; 16: 143. PMID: 26908167, PMCID: PMC4763445, PII: 10.1186/s12885-016-2198-0, DOI: 10.1186/s12885-016-2198-0, ISSN: 1471-2407.
Lehmann BD, Jovanovic B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS One. 2016; 11(6): e0157368. PMID: 27310713, PMCID: PMC4911051, PII: PONE-D-16-14357, DOI: 10.1371/journal.pone.0157368, ISSN: 1932-6203.
Lehmann BD, Pietenpol JA. Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast [print-electronic]. 2015 Nov; 24 Suppl 2(0 2): S36-40-S40. PMID: 26253813, PMCID: PMC4641762, PII: S0960-9776(15)00147-2, DOI: 10.1016/j.breast.2015.07.009, ISSN: 1532-3080.
Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ, Khabele D. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Oncotarget. 2015 Aug 8/28/2015; 6(25): 21353-68. PMID: 25972361, PMCID: PMC4673270, PII: 3860, DOI: 10.18632/oncotarget.3860, ISSN: 1949-2553.
Lehmann BD, Ding Y, Viox DJ, Jiang M, Zheng Y, Liao W, Chen X, Xiang W, Yi Y. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value. BMC Cancer. 2015 Mar 3/26/2015; 15: 179. PMID: 25886164, PMCID: PMC4404582, PII: 10.1186/s12885-015-1102-7, DOI: 10.1186/s12885-015-1102-7, ISSN: 1471-2407.
Lehmann BD, Pietenpol JA, Tan AR. Triple-negative breast cancer: molecular subtypes and new targets for therapy. Am Soc Clin Oncol Educ Book. 2015; e31-9-e39. PMID: 25993190, PII: 00115000e31, DOI: 10.14694/EdBook_AM.2015.35.e31, ISSN: 1548-8756.
Mohni KN, Thompson PS, Luzwick JW, Glick GG, Pendleton CS, Lehmann BD, Pietenpol JA, Cortez D. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. PLoS One. 2015; 10(5): e0125482. PMID: 25965342, PMCID: PMC4428765, PII: PONE-D-14-51553, DOI: 10.1371/journal.pone.0125482, ISSN: 1932-6203.
Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: implications for therapy. Cancer [print-electronic]. 2015 Jan 1/1/2015; 121(1): 8-16. PMID: 25043972, PMCID: PMC4270831, DOI: 10.1002/cncr.28914, ISSN: 1097-0142.
Guo Y, Zhao S, Lehmann BD, Sheng Q, Shaver TM, Stricker TP, Pietenpol JA, Shyr Y. Detection of internal exon deletion with exon Del. BMC Bioinformatics. 2014 Oct 10/16/2014; 15(1): 332. PMID: 25322818, PMCID: PMC4288651, PII: 1471-2105-15-332, DOI: 10.1186/1471-2105-15-332, ISSN: 1471-2105.
Feigin ME, Akshinthala SD, Araki K, Rosenberg AZ, Muthuswamy LB, Martin B, Lehmann BD, Berman HK, Pietenpol JA, Cardiff RD, Muthuswamy SK. Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer. Cancer Res [print-electronic]. 2014 Jun 6/1/2014; 74(11): 3180-94. PMID: 24662921, PMCID: PMC4096808, PII: 0008-5472.CAN-13-3415, DOI: 10.1158/0008-5472.CAN-13-3415, ISSN: 1538-7445.
Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clin Cancer Res. 2014 Feb 2/15/2014; 20(4): 782-90. PMID: 24536073, PMCID: PMC3962777, PII: 1078-0432.CCR-13-0583, DOI: 10.1158/1078-0432.CCR-13-0583, ISSN: 1557-3265.
Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov [print-electronic]. 2014 Feb; 4(2): 232-45. PMID: 24356096, PMCID: PMC3946308, PII: 2159-8290.CD-13-0286, DOI: 10.1158/2159-8290.CD-13-0286, ISSN: 2159-8290.
Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014 Jan; 232(2): 142-50. PMID: 24114677, PMCID: PMC4090031, DOI: 10.1002/path.4280, ISSN: 1096-9896.
Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, Vnencak-Jones CL, Ross JS, Pietenpol JA, Sosman JA, Puzanov I, Miller VA, Pao W. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res. 2013 Dec 12/15/2013; 19(24): 6696-702. PMID: 24345920, PMCID: PMC3880773, PII: 19/24/6696, DOI: 10.1158/1078-0432.CCR-13-1746, ISSN: 1557-3265.
Xiang Y, Qiu Q, Jiang M, Jin R, Lehmann BD, Strand DW, Jovanovic B, DeGraff DJ, Zheng Y, Yousif DA, Simmons CQ, Case TC, Yi J, Cates JM, Virostko J, He X, Jin X, Hayward SW, Matusik RJ, George AL, Yi Y. SPARCL1 suppresses metastasis in prostate cancer. Mol Oncol [print-electronic]. 2013 Dec; 7(6): 1019-30. PMID: 23916135, PMCID: PMC3838491, PII: S1574-7891(13)00105-1, DOI: 10.1016/j.molonc.2013.07.008, ISSN: 1878-0261.
Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans WF, Ueno NT. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res [print-electronic]. 2013 Oct 10/1/2013; 19(19): 5533-40. PMID: 23948975, PMCID: PMC3813597, PII: 1078-0432.CCR-13-0799, DOI: 10.1158/1078-0432.CCR-13-0799, ISSN: 1557-3265.
Qiu Q, Lu P, Xiang Y, Shyr Y, Chen X, Lehmann BD, Viox DJ, George AL, Yi Y. A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer. PLoS One [print-electronic]. 2013; 8(1): e54979. PMID: 23383020, PMCID: PMC3558433, PII: PONE-D-12-15536, DOI: 10.1371/journal.pone.0054979, ISSN: 1932-6203.
Lehmann BD, Pietenpol JA. Targeting mutant p53 in human tumors. J Clin Oncol [print-electronic]. 2012 Oct 10/10/2012; 30(29): 3648-50. PMID: 22965952, PII: JCO.2012.44.0412, DOI: 10.1200/JCO.2012.44.0412, ISSN: 1527-7755.
Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, Pietenpol JA. TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Cancer Inform [print-electronic]. 2012; 11: 147-56. PMID: 22872785, PMCID: PMC3412597, PII: cin-11-2012-147, DOI: 10.4137/CIN.S9983, ISSN: 1176-9351.
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011 Jul; 121(7): 2750-67. PMID: 21633166, PMCID: PMC3127435, PII: 45014, DOI: 10.1172/JCI45014, ISSN: 1558-8238.
Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Res [print-electronic]. 2010; 12(3): R41. PMID: 20576088, PMCID: PMC2917036, PII: bcr2595, DOI: 10.1186/bcr2595, ISSN: 1465-542X.
Available Postdoctoral Position Details
Posted: 5/2/2023
The laboratory of Jennifer Pietenpol and Brian Lehmann at Vanderbilt University Medical Center is seeking a highly motivated postdoctoral candidate to study epigenetic mechanisms of tumor immune cell escape. The lab is focused on translational breast cancer research that advances treatment strategies for triple-negative breast cancer. The successful candidate will engage productively on a project defining novel mechanisms of immune cell evasion by cancer cells. The candidate will utilize cell culture, syngeneic animal models, human tissues and data science to advance our understanding of tumor immune suppression and develop pre-clinical data for future clinical trials for breast cancer.
Please visit the lab website for more information: https://www.vumc.org/pietenpol-lab/welcome
The laboratory welcomes candidates to apply who will be receiving shortly or have recently received a Ph.D. in molecular biology, cancer biology, immunology or a related field. The candidate is expected to plan, design, and conduct highly technical and complex research projects independently and in consultation with the Principal Investigators, analyze research data and provide interpretations and contribute to the development of research documentation for publication. Vanderbilt University Medical Center offers a highly collaborative research environment, that has as its first pillar the people who form the team - “We nurture a caring, culturally sensitive, and professional atmosphere as we continuously invest in the well-being and aspirations of our people.” Ideal candidates will be self-motivated and have strong interpersonal and communication skills and experience in cell biology, molecular biology, data science and basic immunology techniques involving mouse models.
Please send your application with a cover letter stating research interests and career goals, full CV, and contact information for three references to Brian Lehmann, Ph.D. (brian.d.lehmann@vumc.org)